alendronate has been researched along with Cancer of Ovary in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study we used a standardized ATP-based tumor chemosensitivity assay (ATP-TCA) to measure the activity of alendronate, clodronate and zoledronic acid in five ovarian carcinoma cell lines and human solid tumors (breast, lung, ovarian, unknown primary carcinoma, and cutaneous and uveal melanoma) (n=34)." | 3.73 | Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. ( Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M, 2005) |
| "Ovarian cancer is the most lethal gynecological malignancy." | 1.91 | Engineering Bifunctional Calcium Alendronate Gene-Delivery Nanoneedle for Synergistic Chemo/Immuno-Therapy Against HER2 Positive Ovarian Cancer. ( Bi, B; Chen, G; Chen, P; Chen, Y; Chen, ZY; He, Y; Huang, X; Pan, Y; Qiu, M; Zeng, L; Zhao, J, 2023) |
| "We established an in vivo ovarian cancer model with i." | 1.33 | Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. ( Hashimoto, K; Ikebuchi, Y; Kawagishi, R; Morishige, K; Murata, Y; Sakata, M; Sawada, K; Tahara, M; Tasaka, K, 2005) |
| "Treatment of ovarian cancer cells with alendronate resulted in inactivation of Rho, changes of cell morphology, loss of stress fiber formation, and focal adhesion assembly, and the suppression of phosphorylation of myosin light chain and tyrosine phosphorylation of focal adhesion proteins, which are essential processes for cell migration." | 1.31 | Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. ( Ikebuchi, Y; Kawagishi, R; Morishige, K; Murata, Y; Sawada, K; Tahara, M; Tasaka, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G | 1 |
| Zeng, L | 1 |
| Bi, B | 1 |
| Huang, X | 1 |
| Qiu, M | 1 |
| Chen, P | 1 |
| Chen, ZY | 1 |
| He, Y | 1 |
| Pan, Y | 1 |
| Chen, Y | 1 |
| Zhao, J | 1 |
| Parente-Pereira, AC | 1 |
| Shmeeda, H | 1 |
| Whilding, LM | 1 |
| Zambirinis, CP | 1 |
| Foster, J | 1 |
| van der Stegen, SJ | 1 |
| Beatson, R | 1 |
| Zabinski, T | 1 |
| Brewig, N | 1 |
| Sosabowski, JK | 1 |
| Mather, S | 1 |
| Ghaem-Maghami, S | 1 |
| Gabizon, A | 1 |
| Maher, J | 1 |
| Schott, S | 1 |
| Wallwiener, M | 1 |
| Kootz, B | 1 |
| Seeger, H | 1 |
| Fehm, T | 1 |
| Neubauer, H | 1 |
| Sawada, K | 2 |
| Morishige, K | 2 |
| Tahara, M | 2 |
| Kawagishi, R | 2 |
| Ikebuchi, Y | 2 |
| Tasaka, K | 2 |
| Murata, Y | 2 |
| Hashimoto, K | 1 |
| Sakata, M | 1 |
| Knight, LA | 1 |
| Conroy, M | 1 |
| Fernando, A | 1 |
| Polak, M | 1 |
| Kurbacher, CM | 1 |
| Cree, IA | 1 |
| Lappe, JM | 1 |
| Tinley, ST | 1 |
7 other studies available for alendronate and Cancer of Ovary
| Article | Year |
|---|---|
Engineering Bifunctional Calcium Alendronate Gene-Delivery Nanoneedle for Synergistic Chemo/Immuno-Therapy Against HER2 Positive Ovarian Cancer.
Topics: Alendronate; Animals; Calcium; Cell Line, Tumor; Female; Humans; Ovarian Neoplasms; T-Lymphocytes | 2023 |
Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Topics: Alendronate; Animals; Carcinoma; Cell Line, Tumor; Cytotoxicity, Immunologic; Female; Humans; Immuni | 2014 |
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Alendronate; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Death; | 2012 |
Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho.
Topics: Alendronate; Cell Movement; Cell Survival; Cytoskeletal Proteins; Diterpenes; Drug Interactions; Enz | 2002 |
Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.
Topics: Alendronate; Animals; CA-125 Antigen; Cell Line, Tumor; Disease Progression; Female; Mice; Mice, Inb | 2005 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemoth | 2005 |
Prevention of osteoporosis in women treated for hereditary breast and ovarian carcinoma: a need that is overlooked.
Topics: Adult; Alendronate; Breast Neoplasms; Calcitonin; Diet; Diphosphonates; Exercise Therapy; Female; Hu | 1998 |